Developing a CHA2DS2‐VASc score ≥2 within 3 months				Developing a CHA2DS2‐VASc score ≥2 within 12 months
	Male baseline score = 0 <65 years	Male baseline score = 1 <65 years	Male baseline score = 1 ≥65 years	Female baseline score = 1 <65 years	Male baseline score = 0 <65 years	Male baseline score = 1 <65 years	Male baseline score = 1 ≥65 years	Female baseline score = 1 <65 years
Age (per year increase)	1.11 (1.09‐1.13)	1.11 (1.09‐1.13)	1.10 (1.08‐1.13)	1.10 (1.08‐1.12)	1.11 (1.09‐1.12)	1.16 (1.14‐1.18)	1.18 (1.16‐1.20)	1.20 (1.17‐1.22)
HAS‐BLED score = 1 (vs HAS‐BLED score = 0)	1.86 (1.45‐2.39)	1.23 (1.03‐1.48)	0.61 (0.51‐0.72)	1.22 (0.98‐1.52)	1.94 (1.61‐2.35)	1.32 (1.15‐1.52)	0.63 (0.54‐0.72)	1.36 (1.17‐1.58)
HAS‐BLED score = 2 (vs HAS‐BLED score = 0)	3.66 (2.46‐5.43)	1.36 (1.04‐1.78)	0.76 (0.64‐0.90)	2.28 (1.56‐3.32)	3.98 (2.96‐5.36)	1.70 (1.4‐2.07)	0.81 (0.70‐0.93)	2.39 (1.83‐3.11)
HAS‐BLED score ≥3 (vs HAS‐BLED score = 0)	0.99 (0.14‐7.05)	1.01 (0.52‐1.97)	‐	3.06 (1.26‐7.45)	4.52 (2.13‐9.61)	1.62 (1.04‐2.52)	‐	2.21 (0.99‐4.95)
Contribution to the baseline CHA2DS2‐VASc score
Congestive heart failure	‐	1.52 (1.16‐1.99)	‐	‐	‐	1.46 (1.17‐1.82)	‐	‐
Hypertension	‐	1.02 (0.84‐1.24)	‐	‐	‐	0.97 (0.84‐1.13)	‐	‐
Diabetes	‐	1.31 (1.01‐1.71)	‐	‐	‐	1.31 (1.07‐1.60)	‐	‐